Home » Topics » Disease categories and therapies » Dermatologic

Dermatologic
RSS

Positive phase III results for new Solarase formulation

June 21, 1996

5alpha-reductase type 1 inhibitors from Merck & Co.

June 21, 1996

Botulinum toxin type A as dermatology remedy

June 14, 1996

Positive phase III results for Phytopharm's Zemaphyte

June 14, 1996

Amgen reveals polypeptide KGF analogues

June 14, 1996

Excellent preclinical results of Repel announced

June 14, 1996

New topical corticosteroids from Hoechst

June 14, 1996

Favorable trial results with interferon gamma-1b for atopic dermatitis and keloids

June 7, 1996

Collagen Corp. acquires distribution rights to Tissue Technologies' ePTFE implant

June 7, 1996

Synthetic retinoid analogue cleared for U.S. market

June 7, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...